# Therapeutic Potential of Polymer-Coated Mesoporous Silica Nanoparticles
## 2 Polymer Coated MSNs for Cancer
\begin{table}
\begin{tabular}{l l l l l l} \hline
**Sr No** & **Investigators** & **Silica Core** & **Polymer Used** & **Drug** & **Application** \\ \hline
23 & [PERSON] et al. [42] & MSNs encapsulated in liposomes & Poly(acrylic acid) & Arsenic dioxide & Clioma \\ \hline
24 & [PERSON] et al. [47] & MCM-41 & Chitosan and Sodium alginate & Pramipescale & Neunoblastoma \\ \hline
25 & [PERSON] et al. [48] & MSNs & Poly(lactic acid) & Resveratrol & Parkinson’s disease \\ \hline
26 & [PERSON] et al. [49] & MSNs & plasmid RhoC-DsRed & Curcumin & Oxidative stress \\ \hline
27 & [PERSON] et al. [50] & MSNs & PEG & Quercetin, myrietin and & Oxidative stress \\ \hline
28 & [PERSON] et al. [51] & MSNs & Poly(N-isopropylacrylamide-co-3-(methoxy/isopropyl)) & Ibuprofen & Inflammation \\ \hline
29 & Galin-Sarfaz & MSNs & PEI and PEG & Dexamethasone & Pulmonary Inflammation \\ \hline
30 & [PERSON] et al. [52] & SBA-15 and MCM-41 & Eudragit S and Eudragit RL & Sulfasalazine & inflammatory bowel disease \\ \hline
31 & [PERSON] et al. [54] & Gold nanorods coated & PEG & Indocyanine green & Light-induced imaging-guided cancer therapy \\ \hline
32 & [PERSON] et al. [58] & FITC-MSNs & Polydopamine and Graphene oxide & Cipplatin & Theranostic Cancer therapy \\ \hline
33 & [PERSON] et al. [56] & MSNs & Poly Curcumin & DOX & Theranostic Cancer therapy \\ \hline
34 & [PERSON] et al. [57] & SBA-15 & Polydopamine & Silver & Antibacterial therapy \\ \hline
35 & [PERSON] et al. [58] & SBA-15 Nanowiskhers & Tannic acid & Metronidazoleazole & Trichomasis \\ \hline
36 & [PERSON] et al. [59] & MSNs & Nafion Polymer & Gentamicin & Immunoassay \\ \hline
37 & [PERSON] et al. [60] & Lithium Doped Silica Nanospheres & Polydopamine & Polybetweenher ketone & Bone regeneration \\ \hline
38 & [PERSON] et al. [61] & MSNs & Disearyl phosphatidylcholine & Rhodamine- B & Osteoarthritis \\ \hline
39 & Ngamchedrrakal & MSNs & PEI and PEG & siRNA & Gene Delivery \\ \hline
40 & [PERSON] et al. [63] & Phosphonate modified MSNs & PEI & Plasmid DNA and & Gene delivery \\ \hline
41 & [PERSON] et al. [64] & Lanthanide doped upconversion & PEG & siRNA and hypercellin A & Gene delivery \\ \hline
42 & [PERSON] et al. [65] & MCM-41 & PAMAM dendrimer and chitosan-gelatine scaffold & Insulin and & Diabetes \\ \hline \end{tabular}
\end{table} 
Table 2: _Cont._Likewise, gold core@shell MSNs have also been investigated in cancer chemo-photothermal therapy. These MSNs (nanorods) were coated with poly-2-ethyl-2-oxazoline in order to increase the biocompatibility and blood circulation time. Polymer coated MSNs were able to load more DOX compared to bare MSNs and provide a slow and controlled release of drug. It was observed that polymer coating leads to the improvement of the performance of gold core MSNs for multifunctional combinatorial cervical cancer therapy [43]. [PERSON] et al. used a temperature and ROS dual responsive polymer, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl acrylate, to coat MSNs for the stimuli sensitive delivery of DOX. The drug was loaded at low temperature (4\({}^{\circ}\) C) and the pores were then blocked by raising the temperature (37\({}^{\circ}\) C). A zero burst release was observed under physiological conditions, whereas a rapid release of cargo was observed in the presence of H\({}_{2}\)O\({}_{2}\) due to the phase transition of coated polymer from hydrophobic to hydrophilic [44]. [PERSON] et al. developed MSNs coated with lipid galactosylceramide for the sustained delivery of hydroxycampotthecine. The MSNs were prepared by a modified Stober method and the lipid membrane was coated on the MSN surface using a lipid film hydration method. These nanoparticles showed that up to 30% of drug loading and approx. 48% of the drug was released in a simulated tumor environment in a sustained manner. The cell viability studies using these nanoparticles suggested that drug loaded nanoparticles had up to three times more stronger inhibitory effects on hepatocellular carcinoma cells compared to free hydroxycampotthecine [45]. [PERSON] et al.